Showing results (41-50 of 335) with videos related to
Sort By:
Pageof 34
European Journal of Cancer (Oxford, England : 1990)|November 3, 2007
Medicinal cannabis in oncologyFrederike K Engels, Floris A de Jong, Ron H J Mathijssen, et al.Frontiers in Pharmacology|April 17, 2020
Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of TamoxifenLena Klopp-Schulze, Anna Mueller-Schoell, Patrick Neven, et al.Clinical Pharmacology and Therapeutics|April 25, 2022
Model-Based Prediction of Irinotecan-Induced Grade 4 Neutropenia in Advanced Cancer Patients: Influence of Demographic and Clinical FactorsSpinel Karas, Ron H J Mathijssen, Ron H N van Schaik, et al.Journal for Immunotherapy of Cancer|October 23, 2020
Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanomaDaan P Hurkmans, Christina Jensen, Stijn L W Koolen, et al.Clinical Pharmacology and Therapeutics|February 12, 2024
Model-Based Prediction of Irinotecan-Induced Grade 4 Neutropenia in Cancer Patients: Influence of Incorporating Germline Genetic Factors in the ModelSpinel Karas, Ron H J Mathijssen, Ron H N van Schaik, et al.The Oncologist|September 4, 2007
Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?Ron H J Mathijssen, Floris A de Jong, Walter J Loos, et al.European Journal of Cancer (Oxford, England : 1990)|April 17, 2026
Associations between early loss of skeletal muscle and osimertinib trough concentrations in patients with advanced EGFR-mutated NSCLCBarend J Sikkema, Marijn Veerman, Esther Oomen-de Hoop, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 2, 2021
Taste, smell and mouthfeel disturbances in patients with gastrointestinal stromal tumors treated with tyrosine-kinase inhibitorsJip M van Elst, Nikki S IJzerman, Ron H J Mathijssen, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 23, 2024
Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The NetherlandsRenaud J S D Heine, Ron H J Mathijssen, Floor A J Verbeek, et al.British Journal of Clinical Pharmacology|September 14, 2016
A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patientsEvelien J M Kuip, Maarten L Zandvliet, Stijn L W Koolen, et al.Pageof 34